<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380964</url>
  </required_header>
  <id_info>
    <org_study_id>GEE006.10</org_study_id>
    <nct_id>NCT01380964</nct_id>
  </id_info>
  <brief_title>Research of Biomarkers in Duchenne Muscular Dystrophy Patients</brief_title>
  <acronym>IBISD</acronym>
  <official_title>Research of Biomarkers for Disease Diagnosis, Disease Monitoring and Therapeutic Treatment Response in Duchenne Muscular Dystrophy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Myology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify potential biomarkers for the diagnosis, disease
      progression assessment and response to treatment in patients with Duchenne Muscular
      Dystrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IBiSD aims to identify and validate new and disease-specific biomarkers.</measure>
    <time_frame>End of study</time_frame>
    <description>This study will establish the relevance of urinary and blood biomarkers for the diagnosis, follow-up and assessment of treatment response in patients with DMD (IBiSD1, 2 and 4). IBiSD will also attempt to establish the seroprevalence to the different strains of AAV in patients with DMD (IBiSD3).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">220</enrollment>
  <condition>Duchenne Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>DMD patients</arm_group_label>
    <description>DMD Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <description>Control patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, serum, t lymphocytes, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Duchenne Muscular Dystrophy controls (healthy or patients with a non-related
        disease)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FOR PATIENTS:

          -  Diagnosis of DMD confirmed by genetic testing

          -  Age over 3 years

          -  Weight over 15 kg

          -  Informed consent signed

          -  FOR CONTROLS:

          -  Age over 3 years

          -  Male gender

          -  Weight over 15 kg

          -  Subjects with national health insurance coverage

          -  Informed consent signed

          -  Nonacute or chronic muscular, allergic, infectious, endocrine or inflammatory disorder
             in the 3 weeks preceding inclusion

        Exclusion Criteria:

          -  FOR PATIENTS:

          -  Concomitant chronic or acute muscular, endocrine, infectious, allergic or inflammatory
             disorder in the three weeks preceding the blood test

          -  Intake of medicines other than angiotensin-converting enzyme inhibitors, beta
             blockers, dietary supplements, vitamins, alendronate and methylphenidate. Steroids
             (and medicines prescribed with them such as calcium supplements and proton pump
             inhibitors) will be discussed

          -  Mental retardation or autism

          -  Vaccination or treatment with immunoglobulins within the three months preceding
             inclusion

          -  FOR CONTROLS:

          -  Concomitant chronic or acute muscular, neurological (including mental retardation and
             autism), infectious or inflammatory disorder in the three weeks preceding the blood
             test

          -  Vaccination or treatment with immunoglobulins within the three months preceding
             inclusion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent SERVAIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Myology Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Myology</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>biomarkers</keyword>
  <keyword>transcriptomics</keyword>
  <keyword>mironics</keyword>
  <keyword>proteomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

